Recombinant Protein Market

Recombinant Protein Market Outlook (2022-2032)

The global recombinant protein market is set to enjoy a valuation of US$ 457.1 Million in 2022 and further expand at a CAGR of 4.6% to reach US$ 719.5 Million by the end of 2032.

The market has contributed to 10% of the overall drug market. However, it is anticipated to capture large proportion over the forecast period.

Report Attributes	Details
Recombinant Protein Market Size (2021A)	US$ 437 Million
Estimated Market Value (2022E)	US$ 457.1 Million
Forecasted Market Value (2032F)	US$ 719.5 Million
Global Market Growth Rate (2022-2032)	4.6% CAGR
North America Market Share (2021)	~ 32.7%
Europe Market Growth Rate (2022-2032)	~ 4.4% CAGR
United States Market Growth Rate (2022-2032)	~ 5% CAGR
Market Share of Top 5 Companies	~ 31.1%
Key Companies Profiled	A.M.S. Biotechnology (Europe) Limited Bio-Rad Laboratories Inc. BPS Bioscience Inc. Abcam plc PerkinElmer Inc. Crown Bioscience Inc. GenScript Corporation Merck Millipore Limited Sigma Aldrich Company Ltd.

Sales Analysis of Recombinant Protein (2017-2021) Vs. Market Forecast Outlook (2022-2032)

Most human diseases are partly associated with the dysfunction of specific proteins. Thus, growing chronic diseases such as cancer, diabetes, anemia, etc., have created a path for the production of recombinant proteins. Also, augmenting focus on healthcare provides a space for innovation in biologics and biosimilars which also supports the invention in the recombinant proteins market in the past years.

Hence, the sale of recombinant protein has observed noticeable growth during the historical period representing a compound annual growth rate of 4.3%.

Furthermore, the demand for recombinant protein will observe an upward trend during the forecast period due to rising investment in R&D, and escalating demand for protein-based regenerative and therapeutic medicines around the globe.

Apart from healthcare, recombinant proteins are also used in agriculture, food production, and bioengineering which will further increase the demand in near future.

Fact.MR suggests that the global recombinant protein market will be valued at US$ 719.5 Million by 2032 end posing a CAGR of 4.6% since 2022.

• Short Term (2022 Q2 to 2025): Growing cases of chronic diseases and unavoidable viral outbreaks will upsurge the demand for protein-based therapeutic treatments. This will upsurge the growth of the market during the short term forecast period.
• Medium Term (2025-2028): Rising awareness regarding the use of recombinant proteins in food production and agriculture sector will give momentum to the market growth in medium term forecast period.
• Long Term (2028-2032): The government spending on biotechnology for novel innovation and the production of recombinant proteins will provide long-term growth to the market.

Over the 2017-2021 historical period, the global recombinant protein market registered a CAGR of 4.3%, and according to the Fact.MR, a market research and competitive intelligence provider, the market is projected to exhibit growth at 4.6% CAGR between 2022 and 2032.

Market share analysis of recombinant protein based on product type and region is provided in a nutshell in the above image. Under the product type segment, the growth factors sub-segment dominates with 21.3% market share in 2022.

What’s Driving Demand for Recombinant Protein?

“Evolving Generations of Recombinant Protein with Wide Applications Spur the Market Growth’’

Recombinant proteins are not only used in research but also used as a drug to treat various chronic diseases such as dwarfism, congestive heart failure, diabetes, cerebral apoplexy, myocardial infarction, multiple sclerosis, anemia, neutropenia, etc. There are almost more than 130 recombinant proteins that have been approved by US FDA to date. Though, more than 170 recombinant proteins are manufactured and are widely used in medicines across the world.

Moreover, recombinant protein generations came up with some improvements as compared to the previous generation. Such as first-generation recombinant proteins comprised of native structures of proteins, furthermore, the second generation encompassed proteins with enhanced properties such as specificity, biodistribution, and efficacy. Furthermore, the third generation of recombinant protein comprised new formulations and new routes of administration with higher efficacy and safety. Hence, product improvisation is the key contributor to the recombinant protein market growth.

“Significant Rise of Research in Biologics led to Upsurge the Sale of Recombinant Proteins”

The wide growth of healthcare sector across the world supports the investment in research and development to introduce novel solutions for various diseases. The growth of recombinant proteins is directly proportional to the growth of healthcare sector and investment in biologics. Also, government funding led to amplifying the research activities in biotechnological businesses and academic institutes to bring innovations in recombinant proteins market.

The above-mentioned factors are anticipated to fuel the request for recombinant antibodies and recombinant human erythropoietin etc.

What Do Recombinant Protein Manufacturers Need to Watch Out for?

“Complexity of Protein, Its Purification and Protein Expression may Slowdown the Production”

The production of recombinant protein is a complex process owing to complex structure of a protein. For instance, the presence of GPI-anchor or transmembrane domains may mix the target proteins and plasma membranes, which reduces the yield of protein. In addition, the transmembrane is hydrophobic in nature which also disturbs the protein stability.

Additionally, aggregation and over-expression of the target protein may create unexpected physiological variations in the host cells which further results in making misfolded proteins as well as protein degradation by the enzyme protease of the host body.

Hence, process optimization and careful planning are the necessary factors in recombinant protein expression to create an appropriate host, culture duration, and condition. Thus, manufacturers need to watch out aforementioned factors to avoid hindrances in market growth.

Country-wise Insights

Will the High R&D Spending in United States Drive High Demand for Recombinant Protein?

The U.S. is anticipated to grow with a CAGR of 5% during the forecast period. The high growth of recombinant proteins market in U.S. is due to high spending on research and development, government support for innovations, and huge presence of key market players in that country.

Apart from this, the United States is a prominent country for prevalence of chronic diseases such as cancer and diabetes which makes it a noticeable country for innovations in recombinant proteins. Intensifying per capita healthcare spending is also a major factor in the growing acceptance of recombinant proteins in the U.S.

Why Recombinant Protein Market Expected to Be Highly Opportunistic in Japan?

Japan is the key contributor to the growth of the recombinant protein market in the APAC region. The dominance is due to huge government support and the growing biotechnology industry in Japan. For instance, the government of Japan has financed Okinawa Health Biotechnology Research and Development Center, which offers free research amenities to capable biotechnology companies.

The manufacturers who are willing to invest in international markets, Japan, and Asian markets will provide incredible opportunities for collaborations and business developments.

Category-wise Insights

Which Product Type is Most Widely Used?

The recombinant protein under the product type segment is categorized into Immune checkpoint regulators, chemokines, growth factors, cytokines, colony-stimulating factors, hormones, enzymes & inhibitors, and others. Amongst them, the recombinant growth factors sub-segment holds the largest market share of 21.3% of the global market in 2021 and is expected to witness a CAGR of 4.5% during the forecast years of 2022-2032.

Recombinant growth factors have gained popularity in the market owing to their wide array of applications. Various recombinant growth factors have been verified for their capability to quicken chronic wound healing in diabetic patients. Apart from this, one of the prominent applications of recombinant growth factors in clinical nephrology. It acts as a growth hormone in children who suffer from growth failure with chronic renal failure. Hence, the wide applications of recombinant growth factors give them popularity among other recombinant proteins.

Which application is estimated to support marker growth in recombinant protein market during the forecast period?

In terms of applications, recombinant proteins are segmented into drug discovery & development, basic research, toxicity screening, biopharmaceutical production, drug screening, tissue engineering, and forensic testing. Which, the basic research segment holds the majority of the share in the global market. It is anticipated to follow the same trend during the forecast period. The basic research segment is projected to hold 55.1% share of the market by 2032.

To clarify the fundamental and basic principle of an organism can be carried with the help of recombinant protein. They can be useful to locate and identify the location of protein determined by a specific gene and to reveal the role of other genes such as metabolism, replication, growth, translation, transcription, etc. Hence, due to the above-mentioned ability, recombinant proteins are widely used in cell biology, molecular biology, structural and biophysical studies, biochemistry, and several other research areas.

Competitive Landscape

Prominent recombinant protein manufacturers are A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories Inc., BPS Bioscience Inc., Abcam plc, PerkinElmer Inc., Crown Bioscience Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech Inc., Thermo Fisher Scientific Inc.

Key market players are focusing on products to widen the applications of recombinant proteins in various industries by investing in R&D. Investment to bring novel products into the market is the key strategy among the market leaders. Apart from this, acquisitions, partnerships, and collaborations are some in-organic growth tactics that support maintaining their position in the market.

• In August 2022, Chinese biotechnology company Bao Pharmaceuticals reported that it had raised more than US$ 100 million in a Series B investment round. The company focuses on the commercialization of recombinant protein therapeutics and antibody drugs. The funding was meant to be used for the creation and marketing of medicines made from recombinant proteins. This round was won by Oriental Fortune Capital.
• In March 2020, AMS Biotechnology launched its recombinant protein for the detection of COVID-19 and related RNA viruses. The product launch helped the company to achieve high revenue during the pandemic period.

Fact.MR has provided detailed information about the price points of key manufacturers of recombinant protein positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Key Segments in Recombinant Protein Industry Research

• By Product Type :

  • Immune Checkpoint Regulators
  • Chemokines
  • Growth Factors
  • Cytokines
  • Colony Stimulating Factors
  • Hormones
  • Enzymes & Inhibitors
  • Other

• By End User :

  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Forensic Science Laboratories
  • Food & Beverage Companies
  • Diagnostic Centers
  • Others

• By Application :

  • Drug Discovery & Development
  • Basic Research
  • Toxicity Screening
  • Biopharmaceutical Production
  • Drug Screening
  • Tissue Engineering
  • Forensic Testing

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & ASEAN
  • Oceania
  • MEA